SCHEMBL7003159

SCHEMBL7003159

CCC1Oc2ccc(CNCc3ccccc3)cc2NC1=O

nearest known ligand 0.74

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.74
HSD17B10 Q99714 4/20 0.49
ALOX15 P16050 2/20 0.49
TP53 P04637 2/20 0.48
POLB P06746 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
THRB P10828 1/20 0.47
MAPK1 P28482 2/20 0.47
USP2 O75604 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HTT P42858 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 1/20 0.45
TSHR P16473 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7001004 0.91 PARP1 (0.71) PARP1HSD17B10ALOX15TP53POLB
SCHEMBL6992162 0.85 PARP1 (0.55) PARP1HSD17B10TP53POLBSMN1; SMN2
SCHEMBL532477 0.85 PARP1 (1.00) PARP1HSD17B10ALOX15TP53POLB
SCHEMBL6310170 0.83 PARP1 (0.95) PARP1HSD17B10ALOX15TP53POLB
SCHEMBL10267424 0.80 PARP1 (0.88) PARP1TP53POLBSMN1; SMN2
SCHEMBL6302991 0.79 PARP1 (0.90) PARP1TP53POLBSMN1; SMN2USP2
SCHEMBL6305288 0.79 PARP1 (0.88) PARP1HSD17B10TP53POLBSMN1; SMN2
SCHEMBL29498308 0.77 MAOB (0.49) PARP1HSD17B10ALOX15SMN1; SMN2MAPK1
SCHEMBL6991112 0.77 PARP1 (0.53) PARP1HSD17B10TP53POLBSMN1; SMN2
SCHEMBL10262368 0.76 PARP1 (0.82) PARP1HSD17B10ALOX15GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed